27599 Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE
Sigurgeirsson B, Browning J, Tyring S, Szepietowski JC, Rivera-Díaz R, Effendy I, Bruin G, Paguet B, Fu R, Hampele I, Patekar M (2021)
Journal of the American Academy of Dermatology 85(3 (Suppl.): AB154.
Zeitschriftenaufsatz
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Sigurgeirsson, Bardur;
Browning, John;
Tyring, Stephen;
Szepietowski, Jacek C.;
Rivera-Díaz, Raquel;
Effendy, IsaakUniBi ;
Bruin, Gerard;
Paguet, Bertrand;
Fu, Rong;
Hampele, Isabelle;
Patekar, Manmath
Erscheinungsjahr
2021
Zeitschriftentitel
Journal of the American Academy of Dermatology
Band
85
Ausgabe
3 (Suppl.)
Art.-Nr.
AB154
ISSN
0190-9622
Page URI
https://pub.uni-bielefeld.de/record/2969495
Zitieren
Sigurgeirsson B, Browning J, Tyring S, et al. 27599 Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE. Journal of the American Academy of Dermatology. 2021;85(3 (Suppl.): AB154.
Sigurgeirsson, B., Browning, J., Tyring, S., Szepietowski, J. C., Rivera-Díaz, R., Effendy, I., Bruin, G., et al. (2021). 27599 Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE. Journal of the American Academy of Dermatology, 85(3 (Suppl.), AB154. https://doi.org/10.1016/j.jaad.2021.06.630
Sigurgeirsson, Bardur, Browning, John, Tyring, Stephen, Szepietowski, Jacek C., Rivera-Díaz, Raquel, Effendy, Isaak, Bruin, Gerard, et al. 2021. “27599 Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE”. Journal of the American Academy of Dermatology 85 (3 (Suppl.): AB154.
Sigurgeirsson, B., Browning, J., Tyring, S., Szepietowski, J. C., Rivera-Díaz, R., Effendy, I., Bruin, G., Paguet, B., Fu, R., Hampele, I., et al. (2021). 27599 Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE. Journal of the American Academy of Dermatology 85:AB154.
Sigurgeirsson, B., et al., 2021. 27599 Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE. Journal of the American Academy of Dermatology, 85(3 (Suppl.): AB154.
B. Sigurgeirsson, et al., “27599 Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE”, Journal of the American Academy of Dermatology, vol. 85, 2021, : AB154.
Sigurgeirsson, B., Browning, J., Tyring, S., Szepietowski, J.C., Rivera-Díaz, R., Effendy, I., Bruin, G., Paguet, B., Fu, R., Hampele, I., Patekar, M.: 27599 Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE. Journal of the American Academy of Dermatology. 85, : AB154 (2021).
Sigurgeirsson, Bardur, Browning, John, Tyring, Stephen, Szepietowski, Jacek C., Rivera-Díaz, Raquel, Effendy, Isaak, Bruin, Gerard, Paguet, Bertrand, Fu, Rong, Hampele, Isabelle, and Patekar, Manmath. “27599 Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE”. Journal of the American Academy of Dermatology 85.3 (Suppl.) (2021): AB154.
Link(s) zu Volltext(en)
Access Level
Closed Access